cervical cancer Archives -

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment

EC approves Regeneron’s Libtayo for advanced cervical cancer

https://pharmaphorum.com/news/ec-approves-regenerons-libtayo-for-advanced-cervical-cancer/

News/ News/ News/ Oncology/ R&D

Nykode vaccine shows its worth in cervical cancer trial

Phil Taylor cancer vaccine, cervical cancer, HPV, immuno-oncology, Nykode Therapeutics, Oncology, Vaccibody 0 Comment

Adding Nykode Therapeutics’ VB10.16 vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds

Nykode vaccine shows its worth in cervical cancer trial

https://pharmaphorum.com/news/nykode-vaccine-shows-its-worth-in-cervical-cancer-trial/

News/ News/ Oncology

AstraZeneca’s Imfinzi fails in cervical cancer bid

Phil Taylor AstraZeneca, cervical cancer, Imfinzi, immuno-oncology, Keytruda, Merck & Co, Oncology 0 Comment

AstraZeneca’s hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase

AstraZeneca’s Imfinzi fails in cervical cancer bid

https://pharmaphorum.com/news/astrazenecas-imfinzi-fails-in-cervical-cancer-bid/

News/ News/ Oncology

FDA clears Seagen, Genmab’s Tivdak ADC for cervical cancer

Phil Taylor cervical cancer, fda, Genmab, Oncology, regulatory approval, Seagen, Tivdak 0 Comment

Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from

FDA clears Seagen, Genmab’s Tivdak ADC for cervical cancer

https://pharmaphorum.com/news/fda-clears-seagen-genmabs-tivdak-adc-for-cervical-cancer/

News/ News/ Oncology

In a class first, Merck’s Keytruda extends survival in cervical cancer

Phil Taylor cervical cancer, immuno-oncology, Keytruda, Merck & Co, Oncology 0 Comment

Merck & Co’s Keytruda has become the first checkpoint inhibitor to help patients with advanced cervical cancer live

In a class first, Merck’s Keytruda extends survival in cervical cancer

https://pharmaphorum.com/news/in-a-class-first-mercks-keytruda-extends-survival-in-cervical-cancer/

News/ News/ Oncology

Sanofi, Regeneron prep filings for Libtayo in cervical cancer

Phil Taylor cervical cancer, immuno-oncology, Libtayo, Oncology, Regeneron, Sanofi 0 Comment

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a

Sanofi, Regeneron prep filings for Libtayo in cervical cancer

https://pharmaphorum.com/news/sanofi-regeneron-prep-filings-for-libtayo-in-cervical-cancer/

News/ News/ Oncology

Seagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancer

Richard Staines cancer, cervical cancer, fda, Genmab, R&D, Seagen 0 Comment

Seagen and Genmab have announced they have filed their antibody-drug conjugate tisotumab vedotin with the FDA for patients

Seagen and Genmab file ‘trojan horse’ drug with FDA for cervical cancer

https://pharmaphorum.com/news/seagen-and-genmab-file-trojan-horse-cancer-drug-with-fda/

Digital/ News/ News

AI device could be cheaper and more accurate than smear tests

Richard Staines AI, artificial intelligence, cervical cancer, Lancor Scientific 0 Comment

UK startup Lancor Scientific has secured funding to launch a medical device that aims to use artificial intelligence

AI device could be cheaper and more accurate than smear tests

https://pharmaphorum.com/news/ai-device-could-be-cheaper-and-more-accurate-than-smear-tests/

News/ News/ Oncology/ Top stories

FDA approves Keytruda in cervical cancer

Richard Staines cervical cancer, Keytruda, Merck & Co 0 Comment

Merck & Co’s blockbuster Keytruda has been approved in advanced second line cervical cancer, becoming the first drug

FDA approves Keytruda in cervical cancer

https://pharmaphorum.com/news/fda-approves-keytruda-cervical-cancer/

Trending

cervical cancer

Login